📣 VC round data is live. Check it out!
- Public Comps
- Viscofan
Viscofan Valuation Multiples
Discover revenue and EBITDA valuation multiples for Viscofan and similar public comparables like Vidrala, Greif, Huhtamaki, Graphic Packaging and more.
Viscofan Overview
About Viscofan
Viscofan SA is a casing market and offers growth propositions in the food and health sectors outside the traditional business. It engaged in the manufacture, distribution, and marketing of all types of casings and films for food use. Its products include Cellulose, Collagen, Fibrous, Functional solutions, Plastics, Viscofan Veggie, eFAN, and Edileaf. It also manufactures casings, films, and bags obtained through the treatment of plastic polymers. It has a geographic presence in EMEA, APAC, North America, and South America with key revenue generation from EMEA.
Founded
1975
HQ

Employees
5.3K
Website
Sectors
Financials (LTM)
EV
$3B
Valuation Multiples
Start free trialViscofan Financials
Viscofan reported last 12-month revenue of $1B and EBITDA of $348M.
In the same LTM period, Viscofan generated $1B in gross profit, $348M in EBITDA, and $189M in net income.
Revenue (LTM)
Viscofan P&L
In the most recent fiscal year, Viscofan reported revenue of $1B and EBITDA of $342M.
Viscofan is profitable as of last fiscal year, with gross margin of 66%, EBITDA margin of 23%, and net margin of 13%.
Financial data powered by Morningstar, Inc.
Viscofan Stock Performance
Viscofan has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Viscofan's stock price is $67.76.
Viscofan share price decreased by 3.4% in the last 30 days, and by 7.4% in the last year.
Viscofan has an EPS (earnings per share) of $4.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | -1.3% | -3.4% | -3.2% | -7.4% | $4.18 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialViscofan Valuation Multiples
Viscofan trades at 2.2x EV/Revenue multiple, and 9.5x EV/EBITDA.
EV / Revenue (LTM)
Viscofan Financial Valuation Multiples
As of May 17, 2026, Viscofan has market cap of $3B and EV of $3B.
Viscofan has a P/E ratio of 16.1x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Viscofan Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Viscofan Margins & Growth Rates
Viscofan grew revenue by 3% and EBITDA by 4% in the last fiscal year.
In the most recent fiscal year, Viscofan reported gross margin of 66%, EBITDA margin of 23%, and net margin of 13%.
Viscofan Margins
Viscofan Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Viscofan Operational KPIs
Viscofan's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Viscofan's Rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Viscofan's Rule of X is 34% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Viscofan Competitors
Viscofan competitors include Vidrala, Greif, Huhtamaki, Graphic Packaging, Ableprint, Verallia, SCG Packaging, Toyo Seikan, SKC and Ardagh Metal Packaging.
Most Viscofan public comparables operate across Packaging & Containers.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.8x | 1.8x | 5.9x | 5.9x | |||
| 1.0x | 1.0x | 8.1x | 7.2x | |||
| 1.0x | 1.0x | 6.3x | 6.4x | |||
| 1.0x | 1.0x | 6.0x | 6.6x | |||
| 42.6x | 33.0x | 79.9x | 67.8x | |||
| 1.2x | 1.3x | 6.0x | 6.0x | |||
| 1.2x | 1.2x | 9.2x | 9.1x | |||
| 0.7x | 0.7x | 6.9x | — | |||
This data is available for Pro users. Sign up to see all Viscofan competitors and their valuation data. Start Free Trial | ||||||
Viscofan M&A Activity
Viscofan has acquired 1 company to date.
Last acquisition by Viscofan was on February 27th 2025. Viscofan acquired Pet Mania Comércio Internacional for $35M (EV/Revenue multiple of ).
Latest Acquisitions by Viscofan
| Description | Pet Mania Comércio Internacional is a São Paulo-based producer and exporter of animal-derived pet treats. Specializing in beef, chicken, and fish-based chews, the company supplies bulk natural snacks to distributors in Latin America and Europe. Its product range includes dehydrated ears, tendons, and pâtés processed in HACCP-certified facilities. Operating since 2010, Pet Mania sources from Brazilian farms and exports to over 15 countries, emphasizing preservative-free formulations for dogs and cats. |
| HQ Country | |
| HQ City | São Paulo |
| Deal Date | 27 Feb 2025 |
| Valuation | $35M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Viscofan acquisitions and their M&A valuation multiples. Start Free Trial | |
Viscofan Investment Activity
Viscofan has invested in 4 companies to date.
Latest investment by Viscofan was on June 25th 2024. Viscofan invested in MOA in their $3M Series A round (EV/Revenue multiple of ).
Latest Investments by Viscofan
| Description | MOA is an Israel-based food technology company producing sustainable, land-free protein alternatives to address global food demands. It develops high-value, nutritious foods using fermentation and precision processes without arable land dependency. Products target meat and dairy substitutes for B2B supply in plant-based markets. | Inmedical Therapeutics is a UK-based medtech company developing Covergel, a hydrogel barrier for therapeutic endoscopies. The product minimizes perforation risks during procedures like ESD and POEM by sealing mucosal defects. Currently in preclinical trials, Covergel biodegrades within days and integrates with standard endoscopes. Inmedical targets gastroenterology markets in Europe and the United States. | Cocoon Bioscience is a Barcelona-headquartered biotechnology company that produces recombinant growth factors and specialized enzymes critical for cellular agriculture and precision fermentation processes. The firm supplies high-performance FGF2 variants to cultivated meat producers such as Upside Foods and Aleph Farms, enabling efficient cell proliferation and differentiation in serum-free media. Cocoon Bioscience also develops custom media supplements for alternative protein development and regenerative medicine applications in healthcare. Operating GMP-compliant facilities in Spain, the company supports over 50 biotech clients across Europe, North America, and Asia, focusing on scalable biomanufacturing solutions for nutrition sectors. | Cocoon Bioscience is a Barcelona-headquartered biotechnology company that produces recombinant growth factors and specialized enzymes critical for cellular agriculture and precision fermentation processes. The firm supplies high-performance FGF2 variants to cultivated meat producers such as Upside Foods and Aleph Farms, enabling efficient cell proliferation and differentiation in serum-free media. Cocoon Bioscience also develops custom media supplements for alternative protein development and regenerative medicine applications in healthcare. Operating GMP-compliant facilities in Spain, the company supports over 50 biotech clients across Europe, North America, and Asia, focusing on scalable biomanufacturing solutions for nutrition sectors. | |
| HQ Country | |||||
| HQ City | Pamplona | Vitoria-Gasteiz | Madrid | Madrid | |
| Deal Date | 25 Jun 2024 | 17 Jan 2024 | 3 Nov 2023 | 14 Mar 2023 | |
| Round | Series A | Seed | Seed | Undisclosed stage | |
| Raised | $3M | $900K | $2M | $16M | |
| Investors | Banco Sabadell; Clave Mayor; ICOS Capital Management; SODENA; Viscofan | Gestion De Capital Riesgo Del Pais Vasco; Viscofan | Bexen Medical; Cleon Capital; Columbus Venture Partners; Mondragon Health; North South Ventures; Sangha Capital; Spri; Viscofan | Algenex; BeAble Capital; Cleon Capital; Columbus Venture Partners; Gestion De Capital Riesgo Del Pais Vasco; North South Ventures; Sangha Capital; Viscofan | |
| Valuation | undisclosed | undisclosed | undisclosed | $87M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Viscofan investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Viscofan
| When was Viscofan founded? | Viscofan was founded in 1975. |
| Where is Viscofan headquartered? | Viscofan is headquartered in Spain. |
| How many employees does Viscofan have? | As of today, Viscofan has over 5K employees. |
| Who is the CEO of Viscofan? | Viscofan's CEO is Jose Antonio Canales Garcia. |
| Is Viscofan publicly listed? | Yes, Viscofan is a public company listed on Bolsa de Madrid. |
| What is the stock symbol of Viscofan? | Viscofan trades under VIS ticker. |
| When did Viscofan go public? | Viscofan went public in 1990. |
| Who are competitors of Viscofan? | Viscofan main competitors include Vidrala, Greif, Huhtamaki, Graphic Packaging, Ableprint, Verallia, SCG Packaging, Toyo Seikan, SKC, Ardagh Metal Packaging. |
| What is the current market cap of Viscofan? | Viscofan's current market cap is $3B. |
| What is the current revenue of Viscofan? | Viscofan's last 12 months revenue is $1B. |
| What is the current revenue growth of Viscofan? | Viscofan revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Viscofan? | Current revenue multiple of Viscofan is 2.2x. |
| Is Viscofan profitable? | Yes, Viscofan is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Viscofan? | Viscofan's last 12 months EBITDA is $348M. |
| What is Viscofan's EBITDA margin? | Viscofan's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Viscofan? | Current EBITDA multiple of Viscofan is 9.5x. |
| What is the current FCF of Viscofan? | Viscofan's last 12 months FCF is $136M. |
| What is Viscofan's FCF margin? | Viscofan's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of Viscofan? | Current FCF multiple of Viscofan is 24.4x. |
| How many companies Viscofan has acquired to date? | As of May 2026, Viscofan has acquired 1 company. |
| What was the largest acquisition by Viscofan? | $35M acquisition of Pet Mania Comércio Internacional on 27th February 2025 was the largest M&A Viscofan has done to date. |
| What companies Viscofan acquired? | Viscofan acquired Pet Mania Comércio Internacional. |
| In how many companies Viscofan has invested to date? | As of May 2026, Viscofan has invested in 4 companies. |
| What was the last Viscofan investment? | On 25th June 2024 Viscofan invested in MOA, participating in a $3M Series A round, alongside Banco Sabadell, Clave Mayor, ICOS Capital Management, and SODENA. |
| In what companies Viscofan invested in? | Viscofan invested in Cocoon Bioscience, MOA, Inmedical Therapeutics, and InsektLabel Biotech. |
See public comps similar to Viscofan
Lists including Viscofan
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

